Advertisement
Advertisement
CUE
Cue Biopharma, Inc.
0.32
USDSponsored
+0.01
+1.87%
Feb 06, 15:57 UTC -5
Closed
After-Market
0.32
0.00
-0.31%
CUE Earnings Reports
Positive Surprise Ratio
CUE beat 18 of 29 last estimates.
62%
Next Report
Date of Next Report
Mar 30, 2026
Estimate for Q4 25 (Revenue/ EPS)
$2.52M
/-$0.10
Implied change from Q3 25 (Revenue/ EPS)
+17.50%
/+42.86%
Implied change from Q4 24 (Revenue/ EPS)
+60.22%
/-23.08%
Cue Biopharma, Inc. earnings per share and revenue
On Nov 12, 2025, CUE reported earnings of -0.07 USD per share (EPS) for Q3 25, beating the estimate of -0.09 USD, resulting in a 25.77% surprise. Revenue reached 2.15 million, compared to an expected 2.31 million, with a -7.07% difference. The market reacted with a -7.19% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 3 analysts forecast an EPS of -0.10 USD, with revenue projected to reach 2.52 million USD, implying an increase of 42.86% EPS, and increase of 17.50% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
AYTU BioPharma, Inc. Common Stock
Report Date
Feb 03, 2026 For Q2 26
Estimate
-$0.61
Actual
-$1.05
Surprise
-71.57%
Amgen Inc
Report Date
Feb 03, 2026 For Q4 25
Estimate
$4.82
Actual
$5.29
Surprise
+9.56%
Bristol-Myers Squibb Co.
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.12
Actual
$1.26
Surprise
+11.88%
GSK plc - ADR
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.23
Actual
$0.49
Surprise
+111.36%
Biogen Inc. Common Stock
Report Date
Feb 06, 2026 For Q4 25
Estimate
$1.62
Actual
$1.99
Surprise
+22.39%
Illumina Inc
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.24
Actual
$1.35
Surprise
+8.01%
QIAGEN N.V.
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.64
Actual
$0.62
Surprise
-3.32%
Arrowhead Research Corporation
Report Date
Feb 05, 2026 For Q1 26
Estimate
$0.25
Actual
$0.22
Surprise
-14.76%
Bio-Techne Corp.
Report Date
Feb 04, 2026 For Q2 26
Estimate
$0.44
Actual
$0.46
Surprise
+3.95%
Immunovant, Inc. Common Stock
Report Date
Feb 06, 2026 For Q3 26
Estimate
-$0.72
Actual
-$0.61
Surprise
+16.27%
FAQ
What were Cue Biopharma, Inc.'s earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Cue Biopharma, Inc. reported EPS of -$0.07, beating estimates by 25.77%, and revenue of $2.15M, -7.07% below expectations.
How did the market react to Cue Biopharma, Inc.'s Q3 2025 earnings?
The stock price moved down -7.19%, changed from $0.67 before the earnings release to $0.62 the day after.
When is Cue Biopharma, Inc. expected to report next?
The next earning report is scheduled for Mar 30, 2026.
What are the forecasts for Cue Biopharma, Inc.'s next earnings report?
Based on 3
analysts, Cue Biopharma, Inc. is expected to report EPS of -$0.10 and revenue of $2.52M for Q4 2025.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement